Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial

Gastroenterology

Volumn 146, Issue 7, 2014, Pages

  Forns, Xavier ^a   Lawitz, Eric ^b   Zeuzem, Stefan ^c   Gane, Ed ^d   Bronowicki, Jean Pierre ^e   Andreone, Pietro ^f   Horban, Andrzej ^g   Brown, Ashley ^h   Peeters, Monika ⁱ   Lenz, Oliver ⁱ   Ouwerkerk Mahadevan, Sivi ^j   Scott, Jane ^k   De La Rosa, Guy ^l   Kalmeijer, Ronald ^l   Sinha, Rekha ⁱ   Beumont Mauviel, Maria ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e UNIVERSITÉ DE LORRAINE   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

ⁱ JANSSEN RESEARCH FOUNDATION   (Belgium)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^k Janssen Global Services LLC   (United Kingdom)

^l JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

Chronic Hepatitis C; DAA; Drug; PROMISE

Indexed keywords

BILIRUBIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SIMEPREVIR; VIRUS RNA;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CONFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FUNCTIONAL DISEASE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MALE; NEUTROPENIA; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; RESPIRATORY ACIDOSIS; SEPTIC SHOCK; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE;

CHRONIC HEPATITIS C; DAA; DRUG; PROMISE;

ADULT; AGED; ANTIVIRAL AGENTS; ASIA; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NORTH AMERICA; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84901217985     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.02.051     Document Type: Article

References (43)

1. World Health Organization. WHO fact sheet 164-hepatitis C. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed June 20, 2013.
2. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
3. M.G. Ghany, D.R. Nelson, and D.B. Strader et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
4. M. Omata, T. Kanda, and M.-L. Yu et al. APASL consensus statements and management algorithms for hepatitis C infection Hepatol Int 6 2012 409 435
5. M.W. Fried, M.L. Shiffman, and K.R. Reddy et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
6. M.P. Manns, J.G. McHutchison, and S.C. Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
7. J.G. McHutchison, E.J. Lawitz, and M.L. Shiffman et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
8. C. Berg, F.L. Goncales Jr., and D.E. Bernstein et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin J Viral Hepat 13 2006 435 440
9. D.T. Dieterich, M. Rizzetto, and M.P. Manns Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin J Viral Hepat 16 2009 833 843
10. T. Poynard, M. Colombo, and J. Bruix et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
11. B.R. Bacon, S.C. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
12. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
13. F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
14. S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
15. K.E. Sherman, S.L. Flamm, and N.H. Afdhal et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
16. R.B. Perni, S.J. Almquist, and R.A. Byrn et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 2006 899 909
17. RxList. Victrelis. Available at: http://www.rxlist.com/victrelis-drug/ clinical-pharmacology.htm. Accessed February 3, 2014.
18. M. Buti, K. Agarwal, and Y. Horsmans et al. OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients Hepatology 56 2012 191A 1144A
19. X. Gao, J.M. Stephens, and J.A. Carter et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 2012 335 343
20. C. Hezode Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice Liver Int 32 Suppl 1 2012 32 38
21. C. Hezode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890 J Hepatol 59 2013 434 441
22. H. Qin, H. Li, and X. Zhou et al. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials Clin Drug Investig 32 2012 665 672
23. US Food and Drug Administration. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. Available at: http://www.fda.gov/ forconsumers/byaudience/forpatientadvocates/ucm377920.htm. Accessed February 3, 2014.
24. European Medicines Agency. European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/11/ news-detail-001970.jsp&mid=WC0b01ac058004d5c1. Accessed February 3, 2014.
25. S. Tanwar, P.M. Trembling, and G.M. Dusheiko TMC435 for the treatment of chronic hepatitis C Expert Opin Investig Drugs 21 2012 1193 1209
26. TM - Highlights of prescribing information. Available at: http://www.olysio.com/shared/product/olysio/ prescribing-information.pdf. Accessed January 22, 2014.
27. M.W. Fried, M. Buti, and G.J. Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
28. C. Moreno, T. Berg, and T. Tanwandee et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
29. H.W. Reesink, G.C. Fanning, and K.A. Farha et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
30. S. Zeuzem, T. Berg, and E. Gane et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2013 430 441.e6
31. Jacobson IM, Ghalib R, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013;58:1379A, abstract LB-3.
32. M. Manns, H. Reesink, and T. Berg et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 2011 1021 1033
33. Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet, in press.
34. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Lancet, in press.
35. L. Kleinman, M.W. Zodet, and Z. Hakim et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C Qual Life Res 9 2000 499 508
36. M.C. Reilly, A.S. Zbrozek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
37. J.G. McHutchison, M.P. Manns, and A.J. Muir et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
38. P.Y. Kwo Response-guided therapy for HCV Gastroenterol Hepatol (N Y) 7 2011 43 45
39. P. McEwan, Y. Yuan, and G. Litauen et al. Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages J Hepatol 54 2011 S461 abs 1167
40. K.R. Reddy, F. Lin, and F. Zoulim Response-guided and -unguided treatment of chronic hepatitis C Liver Int 32 Suppl 1 2012 64 73
41. Oliver Lenz, Thierry Verbinnen, Bart Fevery, et al. Virology analyses of simeprevir in Phase 2b and 3 studies. Poster P221 presented at: 49th Annual Meeting of the European Association for the Study of the Liver (EASL); April 9 -13 2014; London, UK (abstract number A-627-0016-02686).
42. M. Sherman, E.M. Yoshida, and M. Deschenes et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy Gut 55 2006 1631 1638
43. Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010;52:461A, abstract 278.